Literature DB >> 12879326

The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.

A D Waldman1, G S Rai.   

Abstract

Previous magnetic resonance spectroscopy (MRS) studies have shown increased myo-inositol (MI) and decreased N-acetyl aspartate (NAA) levels in the parieto-occipital lobes of patients with Alzheimer's disease (AD) compared to those with other dementias and normal subjects. This study aimed to establish the quantitative relationship between metabolite ratios and degree of cognitive impairment in patients with mild to moderate AD and sub-cortical ischaemic vascular dementia (SIVD). Forty-four older people with clinical dementia were recruited from a memory clinic and followed up for 2.0-3.5 years; 20 cases were finally classified as probable AD, 18 as SIVD and 6 as mixed type. Mini Mental State Examination (MMSE) and short echo time single voxel automated MRS from the mesial parieto-occipital lobes were performed at the time of initial referral. Spearman rank correlation coefficients were calculated for MMSE scores and measured metabolite ratios MI/Cr, NAA/Cr, Cho/Cr and NAA/MI. The AD group showed a significant correlation between MMSE and NAA/MI (r=0.54, P=0.014) and NAA/Cr (r=0.48, P=0.033), and a negative, non-significant association with MI/Cr (r=-0.41, P=0.072). MI/Cr was negatively correlated with NAA/Cr (r=-0.51, P=0.021). Neither Cho/Cr ratios nor age correlated with cognitive function. The SIVD group showed no correlation between any of the measured metabolite ratios and MMSE score. This study reinforces the specific association between reduced NAA and increased MI levels in the parieto-occipital region and cognitive impairment in AD. MRS may have a role in evaluating disease progression and therapeutic monitoring in AD, as new treatments become available.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879326     DOI: 10.1007/s00234-003-1040-y

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  19 in total

1.  Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease.

Authors:  E Adalsteinsson; E V Sullivan; N Kleinhans; D M Spielman; A Pfefferbaum
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T.

Authors:  P G Antuono; J L Jones; Y Wang; S J Li
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

4.  Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people.

Authors:  Adam D B Waldman; Gurcharan S Rai; James R McConnell; Mahera Chaudry; David Grant
Journal:  Arch Gerontol Geriatr       Date:  2002 Sep-Oct       Impact factor: 3.250

5.  Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.

Authors:  T Ernst; L Chang; R Melchor; C M Mehringer
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

6.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.

Authors:  A Brand; C Richter-Landsberg; D Leibfritz
Journal:  Dev Neurosci       Date:  1993       Impact factor: 2.984

7.  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease.

Authors:  Ruth M Dixon; Kevin M Bradley; Marc M Budge; Peter Styles; A David Smith
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

8.  Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

Authors:  Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

9.  1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease.

Authors:  Kejal Kantarci; Glenn E Smith; Robert J Ivnik; Ronald C Petersen; Bradley F Boeve; David S Knopman; Eric G Tangalos; Clifford R Jack
Journal:  J Int Neuropsychol Soc       Date:  2002-11       Impact factor: 2.892

10.  A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis.

Authors:  S M Leary; P A Brex; D G MacManus; G J Parker; G J Barker; D H Miller; A J Thompson
Journal:  Magn Reson Imaging       Date:  2000-05       Impact factor: 2.546

View more
  16 in total

1.  [MR spectroscopy in dementia].

Authors:  T Hauser; L Gerigk; F Giesel; L Schuster; M Essig
Journal:  Radiologe       Date:  2010-09       Impact factor: 0.635

Review 2.  Neuroradiological findings in vascular dementia.

Authors:  Ali Guermazi; Yves Miaux; Alex Rovira-Cañellas; Joyce Suhy; Jon Pauls; Ria Lopez; Holly Posner
Journal:  Neuroradiology       Date:  2006-11-18       Impact factor: 2.804

3.  Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

Authors:  Pedro J Modrego; Miguel A Pina; Nicolás Fayed; Marcos Díaz
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study.

Authors:  Zhong-Xian Yang; Shan-Shan Huo; Xiao-Fang Cheng; Zhi-Feng Xu; Zhen Cao; Jie-Xia Zeng; Ye-Yu Xiao; Ke-Zeng You; Wei Chen; Yan-Yan Liu; Ren-Hua Wu
Journal:  Neuroradiology       Date:  2011-07-08       Impact factor: 2.804

Review 5.  Various MRS application tools for Alzheimer disease and mild cognitive impairment.

Authors:  F Gao; P B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

6.  Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy.

Authors:  Emilie A Steffen-Smith; Pamela L Wolters; Paul S Albert; Eva H Baker; Kim C Shimoda; Alan S Barnett; Katherine E Warren
Journal:  Childs Nerv Syst       Date:  2008-02-22       Impact factor: 1.475

7.  Prolonged rote learning produces delayed memory facilitation and metabolic changes in the hippocampus of the ageing human brain.

Authors:  Richard Ap Roche; Sinéad L Mullally; Jonathan P McNulty; Judy Hayden; Paul Brennan; Colin P Doherty; Mary Fitzsimons; Deirdre McMackin; Julie Prendergast; Sunita Sukumaran; Maeve A Mangaoang; Ian H Robertson; Shane M O'Mara
Journal:  BMC Neurosci       Date:  2009-11-20       Impact factor: 3.288

8.  Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy.

Authors:  Natalie M Zahr; Dirk Mayer; Adolf Pfefferbaum; Edith V Sullivan
Journal:  Cereb Cortex       Date:  2008-01-29       Impact factor: 5.357

9.  Postoperative changes in cerebral metabolites associated with cognitive improvement and impairment after carotid endarterectomy: a 3T proton MR spectroscopy study.

Authors:  H Saito; K Ogasawara; H Nishimoto; Y Yoshioka; T Murakami; S Fujiwara; M Sasaki; M Kobayashi; K Yoshida; Y Kubo; T Beppu; A Ogawa
Journal:  AJNR Am J Neuroradiol       Date:  2012-11-01       Impact factor: 3.825

10.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.

Authors:  Madhav Thambisetty; Abdul Hye; Catherine Foy; Eileen Daly; Amanda Glover; Allison Cooper; Andrew Simmons; Declan Murphy; Simon Lovestone
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.